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Abstract
Background: Invasive Staphylococcus aureus infection is increasingly recognised as an important cause of serious sepsis
across the developing world, with mortality rates higher than those in the developed world. The factors determining
mortality in developing countries have not been identified.
Methods: A prospective, observational study of invasive S. aureus disease was conducted at a provincial hospital in
northeast Thailand over a 1-year period. All-cause and S. aureus-attributable mortality rates were determined, and the
relationship was assessed between death and patient characteristics, clinical presentations, antibiotic therapy and
resistance, drainage of pus and carriage of genes encoding Panton-Valentine Leukocidin (PVL).
Principal Findings: A total of 270 patients with invasive S. aureus infection were recruited. The range of clinical
manifestations was broad and comparable to that described in developed countries. All-cause and S. aureus-attributable
mortality rates were 26% and 20%, respectively. Early antibiotic therapy and drainage of pus were associated with a survival
advantage (both p,0.001) on univariate analysis. Patients infected by a PVL gene-positive isolate (122/248 tested, 49%) had
a strong survival advantage compared with patients infected by a PVL gene-negative isolate (all-cause mortality 11% versus
39% respectively, p,0.001). Multiple logistic regression analysis using all variables significant on univariate analysis revealed
that age, underlying cardiac disease and respiratory infection were risk factors for all-cause and S. aureus-attributable
mortality, while one or more abscesses as the presenting clinical feature and procedures for infectious source control were
associated with survival.
Conclusions: Drainage of pus and timely antibiotic therapy are key to the successful management of S. aureus infection in
the developing world. Defining the presence of genes encoding PVL provides no practical bedside information and draws
attention away from identifying verified clinical risk factors and those interventions that save lives.
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Introduction
Staphylococcus aureus is increasingly recognised as an important
cause of serious sepsis in the developing world, where the
associated mortality far exceeds that in developed countries [1–
3]. Adverse outcomes are also observed in countries with growing
economies where available healthcare facilities may vary consid-
erably between major cities and provincial or rural areas. For
example, death attributable to S. aureus bacteraemia in a large,
1,000 bed provincial hospital in Thailand was recently reported to
be 48% [1], roughly double that for well resourced healthcare
settings in Europe and the United States [4–7]. Factors associated
with poor outcome from S. aureus infection in the developed world
include increasing age [6,8], underlying co-morbidities [9],
antimicrobial resistance [10], complicated (disseminated) bacter-
aemia [11], lack of source control [8] including non-removal of
intravenous catheters [12], under-dosing of penicillinase antibiot-
ics for methicillin-susceptible S. aureus (MSSA) [8], and delayed
antibiotic therapy [13]. The relevance of these findings for the
developing world is not directly addressed in the published
literature, but it is likely that low-cost interventions such as timely
administration of antibiotics and drainage of pus which are
advocated as the standard of care elsewhere [14,15] would reduce
poor outcomes in developing country settings. The first aim of this
PLoS ONE | www.plosone.org 1 August 2009 | Volume 4 | Issue 8 | e6512observational study was to identify risk factors for death from S.
aureus infection and determine the effect on outcome of simple
clinical interventions in a provincial hospital in a lower-middle
income setting in Asia.
Panton-Valentine Leukocidin (PVL) is a bicomponent cytotoxin
and a putative S. aureus virulence factor that has been associated
with skin and soft tissue infections [16,17] together with more
severe manifestations including necrotising pneumonia [18,19].
PVL has been strongly associated with the emergence of
community-acquired methicillin-resistant S. aureus (CA-MRSA)
[20,21]. Its role in virulence is currently the subject of much
research and debate within the staphylococcal community, with
some researchers calling for rapid tests to detect the presence of
genes encoding PVL [22,23]. The second aim of this study was to
undertake a cohort study to determine the role of PVL as a risk
factor for death in unselected patients with S. aureus infection.
Methods
Participants and clinical methods
Ethical approval was obtained from the Ethical and Scientific
Review sub-committee of the Royal Thai Government Ministry of
Public Health and the Oxford Tropical Research Ethics
Committee. A prospective, observational study was conducted at
Sappasithiprasong Hospital in northeast Thailand for a period of 1
year, from November 2006 to November 2007. This 1,000-bed
regional hospital serves a catchment of 2 million people and
provides a comprehensive clinical and laboratory service. Potential
study patients were identified by daily consultation with the
hospital diagnostic microbiology laboratory. Patients of any age
with at least one sample taken from a normally sterile site positive
for a pure growth of S. aureus were considered for inclusion. Blood
culture was considered to represent a sterile site sample, and other
sample types were assessed based on details in the clinical notes
and discussion with nursing staff. Surface swabs and other samples
not collected from usually sterile sites or not obtained via
aspiration or an operative procedure were excluded. Patients
were enrolled into the study after written informed consent was
obtained, and were visited daily by study investigators until
discharge to record progress and management. Data were
recorded on standardised forms adapted from those used by
Fowler et al [7]. Final outcome was determined 12 weeks from the
date the first culture positive for S. aureus was taken using a
standardised telephone questionnaire. Some data for the subset of
patients with bacteraemia has been published elsewhere [3].
Definitions
Community-acquired infection was defined as a positive S.
aureus sterile site culture and admission to hospital with an illness
consistent with invasive S. aureus disease. Nosocomial infection was
defined as a positive S. aureus sterile site culture taken more than
48 hours after admission for another condition. Non-nosocomial
healthcare-associated infection was defined as community-ac-
quired infection in an individual who had contact with healthcare
services in the preceding year, using the criteria described by
Fowler et al [7]. Outcomes at 12 weeks were defined as: (i) cure -
clinically improved and no additional sites of infection present or
suspected; (ii) unresolved infection - persistent features of infection
with or without persistent positive cultures; (iii) death attributable
to S. aureus - when death was due to S. aureus infection in a
previously healthy individual or when S. aureus hastened death in
the presence of an underlying condition such as cancer; or (iv)
death due to other causes - in which the S. aureus infection did not
appear to contribute to death.
Laboratory Methods
The hospital diagnostic microbiology laboratory processed all
samples using routine procedures, including antibiotic susceptibil-
ity testing using the disk diffusion method [24]. Susceptibilities
reported to hospital physicians were penicillin, oxacillin, cefazolin,
erythromycin, clindamycin and trimethoprim-sulphamethoxazole
for methicillin-susceptible S. aureus (MSSA), plus vancomycin and
fusidic acid for methicillin-resistant S. aureus (MRSA). A total of
248 S. aureus isolates (first positive sample for each patient, with
preference given to blood culture samples when two different
samples taken on the same day were both positive) were available
and obtained by the investigators, re-identified and stored at
280uC. An extended antibiotic susceptibility profile to cefoxitin,
chloramphenicol, ciprofloxacin, clindamycin, erythromycin, fusi-
dic acid, gentamicin, mupirocin, netilmicin, penicillin, rifampicin,
trimethoprim-sulphamethoxazole, tetracycline and vancomycin
was defined using the disk diffusion method [24]. Isolates that were
resistant to cefoxitin by disk diffusion were further evaluated by
oxacillin and vancomycin E-tests (AB Biodisk). Isolates were
designated as MRSA based on an oxacillin E-test for 248 isolates
re-tested in the research laboratory, and based on the oxacillin disk
diffusion assay for 22 isolates that were tested by the hospital
laboratory but were not available for further testing.
A multiplex polymerase chain reaction (PCR) was used to
determine the presence of mecA, the genes encoding PVL and the
16S rRNA gene (internal positive control). A 1 ml overnight culture
of S. aureus with an optical density of 1.0 at 600 nm was centrifuged
at 16,0006g for 30 seconds and the cell pellet re-suspended with
200 ml phosphate buffer solution (pH 7). Genomic DNA was
extracted using the High Pure PCR Template Preparation Kit
(Roche Applied Science, Germany), with an additional step of
incubation at 37uC for 30 minutes with 0.5 ml of 10 mg/ml
lysostaphin solution (Sigma, USA) prior to cell lysis. The primers
used were as described previously for mecA (primers mA1 and mA2)
[25], the PVL genes (lukS-PV and lukF-PV) [18], and the 16S rRNA
gene (Staph756F and Staph750R) [26] which is genus-specific and
was used as a positive control for each reaction. A 25 ml PCR
reaction was used containing 10–120 ng genomic DNA, 5pmol of
each primer (Proligo Singapore Pty Ltd), 200 mM dNTP (Qiagen,
Germany), 1.25 units of Taq polymerase (Roche Applied Science,
Germany), 4.5 mM MgCl2 and 16buffer. PCR was performed
using a PTC-200 Peltier Thermal Cycler (MJ research, USA). The
PCRconditionswereone cycleof95uCfortwominutes,30cyclesof
15 seconds at 95uC, 15 seconds at 56uC, 45 seconds at 72uC, and a
final step of 72uC for seven minutes. Amplification product size was
determined by reference to a 100-bp molecular weight marker
(Biolabs New England, UK) using 2% agarose gel electrophoresis.
Statistical analysis
Data was double entered into a database. Data analyses were
performed using Stata software version 9 (StataCorp, College
Station, Texas). Categorical data were compared using Fisher’s
exact test and for continuous data Student’s t test was used.
Variables significant at p,0.20 on univariable analysis and with 5
or more events (deaths) were used in the multivariable logistic
regression model. Superficial and deep abscesses were combined
so that there were 5 events. Prematurity was excluded given the
low number of cases overall (n=7). Variables which did not reach
this threshold were reviewed and those considered a priori to
potentially have an important influence on outcome were added
(diabetes mellitus was the only variable in this category). Stepwise
removal and addition of variables were used to determine the final
multivariable model (p for removal 0.1 and p for re-entry 0.05).
Missing PVL data was excluded from the multivariable logistic
S. aureus in Tropics
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regression. Reported p values are two-tailed.
Results
During the study period 295 patients fulfilled the inclusion
criteria. Of these, 270 were recruited and 25 patients did not
participate either because they declined consent (n=21), or
because they had left the hospital by the time the culture became
positive and could not be contacted (n=4). The 270 study patients
had 335 sterile site cultures positive for S. aureus, of which 201 were
pus specimens obtained by aspiration or from operative proce-
dures, 125 were blood cultures, 5 were pleural fluid, 3 were
cerebrospinal fluid (CSF), and one was peritoneal dialysate.
Considering patients as the denominator, 100 patients (37%)
had positive blood cultures of whom 14 had at least one other
positive sterile site culture from an identified focus of infection, and
170 patients had positive pus culture(s) alone.
All-cause mortality at 12 weeks was 70/270 (26%), of which 55/
270 (20%) were attributable to S. aureus infection. Overall mortality
for bacteraemic patients was 53%, compared with 10% in patients
without a positive blood culture (p,0.001). Death occurred in 14/87
(16%) children and 56/183 (31%) adults (p=0.01), of which 14%
and 25% were attributable to S. aureus, respectively. The majority of
infections (191, 71%) were community-acquired, of whom 34 (18%)
died (Table 1). The remainder represented 27 (10%) cases of non-
nosocomial healthcare-associated infection of whom 9 (33%) died,
and 52 (19%) cases of nosocomial infection of whom 27 (52%) died
(p,0.001 for comparison of 3 groups). Most of the 200 patients who
survived to follow up at 12 weeks were cured (n=189). The
remaining 11 patients had a range of unresolved S. aureus infections:
empyema (n=2), diabetic foot infection (n=2), infected orthopaedic
material (n=2), infected pacemaker with endocarditis (n=1),
osteomyelitis plus pyomyositis with (n=1) or without (n=1) septic
arthritis, septic arthritis alone (n=1) or orbital abscess (n=1).
Patient characteristics and their association with outcome are
summarised in Table 1. Age on the day the first culture positive for
S. aureus was taken ranged from 1 day to 92 years (median 39
years). Overall and attributable mortality were significantly
associated with increasing age (p,0.001 for both), and overall
Table 1. Association between patient characteristics and outcome for 270 patients with S. aureus infection.
Overall (n=270) Survivors (n=200) All-cause deaths (n=70) p value*1
Number, % of overall patients Number, % of survivors Number, % of all deaths
Demographics
Age (years); median (IQR) 39 (14–60) 35 (13–53) 55 (32–70) ,0.001
Sex (male) 163 (60%) 121 (61%) 42 (60%) .0.999
Manual labour*
2 (if aged over 16 years) 147 (77%) (n=191) 101 (75%) (n=134) 46 (81%) (n=57) 0.459
- Rice farming*
2 102 (53%) (n=191) 72 (54%) (n=134) 30 (53%) (n=57) .0.999
Co-morbidities
Prematurity/Very low birth weight 7 (3%) 2 (1%) 5 (7%) 0.014
Underlying medical conditions*
3 131 (49%) 81 (41%) 50 (71%) ,0.001
- Diabetes mellitus 42 (16%) 31 (16%) 11 (16%) .0.999
- Immunosuppression*
4 30 (11%) 20 (10%) 10 (14%) 0.377
- Renal disease*
5 25 (9%) 12 (6%) 13 (19%) 0.003
- Cardiac disease*
6 24 (9%) 5 (3%) 19 (27%) ,0.001
- Lung disease*
7 16 (6%) 8 (4%) 8 (11%) 0.036
Source of infection
Community-acquired 191 (71%) 157 (79%) 34 (49%)
Non-nosocomial healthcare-associated 27 (10%) 18 (9%) 9 (13%) ,0.001
Nosocomial 52 (19%) 25 (13%) 27 (39%)
Drug resistance
MRSA 42 (16%) 19 (10%) 23 (33%) ,0.001
Interventions
Effective antibiotic therapy without delay 220 (81%) 175 (88%) 45 (64%) ,0.001
Procedure for infectious source control 184 (68%) 162 (81%) 22 (31%) ,0.001
Data are number (%) unless otherwise stated.
*1p value for the comparison between all-cause deaths and survivors.
*2Denominator for occupation is number of patients over the age of 16 years which is given in each square.
*3Past medical history of any underlying chronic medical conditions reported by the patient/relative or recorded in the medical notes.
*4Immunosuppression from HIV (5 untreated, 3 on anti-retroviral therapy), chemotherapy (n=3), untreated leukaemia (n=1), radiotherapy (n=1) or immunosuppressive
medication including prednisolone more than 30 mg/day for more than 1 week (n=17).
*5Renal disease included end stage renal failure on long-term dialysis (n=3; 2 on haemodialysis, 1 on peritoneal dialysis) and chronic renal failure (not on dialysis) due to
diabetes mellitus (n=14), systemic lupus erythematosus (n=1), multiple myeloma (n=1), glomerulonephritis (n=1) or an unknown aetiology (n=5).
*6Cardiac disease comprised congenital heart disease (n=4), valvular heart disease including rheumatic heart disease (n=8), ischaemic heart disease (n=8), or
arrhythmias including heart block requiring pacemaker (n=4).
*7Lung disease comprised previously treated tuberculosis (n=9), previous empyema (n=1), lung cancer (n=2), long-term tracheostomy (n=1), chronic obstructive
pulmonary disease (n=2) or asthma (n=1).
doi:10.1371/journal.pone.0006512.t001
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prematurity (p=0.014). The presence of pre-existing cardiac,
renal or lung disease was significantly associated with all-cause
mortality and pre-existing cardiac and renal disease with
attributable mortality.
Most of the 270 patients (n=231, 86%) had one or more
identifiable extra-vascular sites of infection, while no site of infection
was identified other than positive blood culture in the remaining 39
cases (Table 2). Superficial and deep abscesses accounted for the
majority of infections (34% and 17%, respectively), and were
strongly associated with a survival benefit (p,0.001 and p=0.004,
respectively). Conversely, respiratory infections and having a blood
culture positive for S. aureus were strongly associated with all-cause
and attributable death (p,0.001 for all comparisons). Patients with
an identified extra-vascular site of infection were less likely to die
than those patients with bacteraemia alone (all-cause 20% vs. 59%,
p,0.001; attributable 16% vs. 56%, p,0.001).
MRSA accounted for 16% (n=42) of infections overall, rising to
26% in those patients with bacteraemia. There was no significant
difference in the MRSA rates between adults and children. No
community-acquired MRSA was identified, the MRSA infections
being defined as nosocomial (n=29, 69%), or non-nosocomial
healthcare-associated (n=13, 31%). MSSA infections were
predominantly community-acquired (84%, n=191), the remain-
der being nosocomial (n=23, 10%) or non-nosocomial healthcare-
associated (n=14, 6%). MRSA infection was positively associated
with all-cause death (p,0.001) (Figure 1), and the association
remained highly significant for attributable mortality (p=0.001).
Table 2. The range of sites of infection in patients and outcome associated with each clinical presentation.
Clinical presentations
Total no. of sites
(n=264)
Total no. of patients
(n=270)
Survivors
(n=200)
All-cause deaths
(n=70) p value*1
Number, % of
all sites
Number, % of overall
patients
Number, % of
survivors
Number, % of all
deaths
Pattern of disease
Bacteraemia only, no identified site of infection 39 (14%) 16 (8%) 23 (33%)
1 identified site of infection 200 (74%) 157 (79%) 43 (61%) ,0.001
.1 identified site of infection 31 (11%) 27 (14%) 4 (6%)
Blood culture positive 100 (37%) 47 (24%) 53 (76%) ,0.001
Superficial abscesses (skin and soft tissue) 89 (34%) 83 (31%) 82 (41%) 1 (1%) ,0.001
Deep abscesses*
2 46 (17%) 44 (16%) 40 (20%) 4 (6%) 0.004
Other skin and soft tissue infections*
3 31 (12%) 30 (11%) 19 (10%) 11 (16%) 0.184
Bone and joint infections 30 (11%) 27 (10%) 24 (12%) 3 (4%) 0.068
- Septic arthritis 16
- Osteomyelitis 8
- Diabetic foot infection 6
Prosthetic material infections 24 (9%) 24 (9%) 17 (9%) 7 (10%) 0.807
- Orthopaedic material*
4 9
- Intravenous device*
5 8
- Pacemaker 3
- Meningitis related to ventriculostomy drain 2
- Arteriovenous graft 1
- Peritonitis from peritoneal dialysis 1
Respiratory infections 23 (9%) 22 (8%) 6 (3%) 16 (23%) ,0.001
- Pneumonia 12
- Empyema 11
Endocarditis*
6 8 (3%) 8 (3%) 6 (3%) 2 (3%) .0.999
Other infections*
7 7 (3%) 7 (3%) 4 (2%) 3 (4%) 0.380
Post-operative infections*
8 6 (2%) 6 (2%) 3 (2%) 3 (4%) 0.182
*1p value for the comparison between all-cause deaths and survivors.
*2Site of deep abscesses were muscle (n=20), retroperitoneal space (n=7), parotid gland (n=7), liver (n=3), lung (n=2), epidural space (n=2), eye (n=2), oropharynx
(n=2) and spleen (n=1).
*3Other skin and soft tissue infections includes: necrotising fasciitis (n=9), bedsore(s) (n=6), pustules and carbuncles (n=5), infected wound from trauma (n=3),
infected wound from tophi (n=2), gangrene (n=2), cellulitis (without other skin or soft tissue lesion) (n=2) and infection of exfoliated skin following a severe drug
reaction (n=2).
*4Orthopaedic material includes: internal fixation metalwork (n=8) and a hip replacement (n=1).
*5Intravenous devices were peripheral cannulas (n=4), central catheters (n=3) and an umbilical catheter (n=1).
*6Endocarditis from transthoracic echocardiographic evidence of vegetations (n=7); 1 case clinically but died prior to echocardiogram.
*7Other infections include: urinary tract infection (n=3), tenosynovitis (n=2), Lemierre’s syndrome (n=1) and corneal ulcer (n=1).
*8Post-operative infections include: mediastinitis (n=4; 3 following mitral valve replacement and 1 after coronary artery bypass graft), meningitis from infected bone
flap surgical wound (n=1) and abdominal wound (n=1).
doi:10.1371/journal.pone.0006512.t002
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single exception being a patient who was discharged from hospital
prior to the culture results becoming available. The majority
(n=253, 94%) of patients commenced antibiotics on or before the
day their positive culture was taken. Of these, 220 patients (87%)
received an empiric antibiotic that covered their infecting strain of
S. aureus as judged by in vitro susceptibility testing. Of the
remainder, 42 patients had a delay in starting antibiotic therapy
to which the organism was susceptible (median delay 3 days, IQR
2–4 days), and 7 patients never received an effective antibiotic. A
delay in receiving effective antibiotic therapy or never receiving
effective therapy was significantly associated with an increased all-
cause mortality (p,0.001) (Figure 2) and attributable mortality
(p,0.001).
A procedure for infectious source control was performed in 184
patients (68%). This was associated with a significantly improved
outcome (p,0.001) (Figure 2). The procedures were: needle
aspiration (n=10), incision and drainage (n=109), debridement
(n=35), joint washout (n=8), removal of prosthesis (n=7),
thoracotomy/decortication (n=4), nephrectomy (n=3), laminec-
Figure 1. Higher all-cause mortality associated with methicillin-resistant S. aureus (MRSA) but not with Panton-Valentine Leukocidin
(PVL). Patients infected by MRSA had a greater all-cause mortality compared with patients infected by methicillin-susceptible S. aureus (MSSA)
(p,0.001). Conversely, patients infected by PVL gene-positive S. aureus had a lower all-cause mortality compared with patients infected by PVL gene-
negative S. aureus (p,0.001), an association that remained after adjustment for MRSA (p=0.001).
doi:10.1371/journal.pone.0006512.g001
Figure 2. Timely effective antibiotic therapy and procedures for infectious source control significantly improved outcome.
Administration of an effective antibiotic on the same day as the positive culture was taken significantly reduced all-cause mortality (p,0.001), as did
undergoing a procedure for infectious source control (p,0.001).
doi:10.1371/journal.pone.0006512.g002
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fasciotomy (n=1), ethmoidectomy (n=1) and craniectomy with
removal of infected bone flap (n=1).
S. aureus isolates from 248 patients were available for PCR, of
which 122 (49%) were PVL gene-positive. All of the PVL gene-
positive isolates were MSSA. The white cell count at the time of
culture was not significantly different between cases infected with
PVL gene-positive isolates and cases infected with PVL gene-
negative isolates (median 15.30610
9/L vs. 14.69610
9/L, respec-
tively, p=0.38). The distribution of clinical presentations in relation
to PVL is shown in Table 3. PVL gene-positive isolates were
significantly more likely to cause skin and soft tissue abscesses
(p,0.001) and deep abscesses (p=0.001) than isolates that were
PVL gene-negative. A significant negative association was observed
between the presence of PVL genes and bacteraemia without a
localising site of infection (p,0.001), prosthetic material infections
(p,0.001) and other skin and soft tissue infections (p=0.026).
Additionally, there was a highly significant negative association
between the presence of PVL genes and all-cause mortality
(p,0.001) (Figure 1), as well as S. aureus-attributable mortality
(p,0.001). This association remained highly significant when
adjusted for MRSA cases (p=0.001). The outcome from pneumo-
nia was poor regardless of PVL, with a mortality rate of 80% for
PVL gene-positive cases and 83% for PVL gene-negative cases.
All variables in Tables 1 and 2 found to be significantly associated
with all-cause and attributable mortality on univariable testing and
with 5 or more events (deaths) together with the presence of PVL
genes, were further analysed using multiple logistic regression to give
the final models shown in Table 4. Cardiac, renal and lung disease
were considered as separate variables for all-cause mortality, and
cardiac and renal disease for attributable mortality. Only cardiac
diseaseremainedineachofthefinalmodels.Age,underlyingcardiac
disease and respiratory infection were positively associated with all-
cause mortality, while one or more abscesses (deep and superficial
combined) as the presenting clinical feature and a procedure for
infectious source control were negatively associated with all-cause
mortality. An analysis of S. aureus-attributable mortality demonstrat-
ed the same associations. Underlying cardiac disease and respiratory
infection had the highest odd ratios for both all-cause mortality and
S. aureus-attributable mortality.
Discussion
Practical, inexpensive solutions are needed to improve the
outcome of bacterial sepsis in developing country settings. Time to
the first dose of effective antibiotics has been related to outcome
for a range of bacterial infectious diseases in the developed world
[13,27], and held true in this study of S. aureus infection. Our
hospital-based study conducted in provincial Thailand is relevant
to the numerous developing countries with growing economies
and expanding healthcare facilities, many of which are in South
and East Asia, where it is possible to identify patients with
suspected bacterial sepsis, administer empiric, broad-spectrum
antibiotics, and drain pus collections. Identification of abscesses
and drainage of pus is fundamental to sepsis control, and the use of
available imaging to investigate patients with S. aureus sepsis and
guide drainage procedures should be a priority. The higher
mortality observed in our study for patients with bacteraemia in
whom a site other than bloodstream was not identified is consistent
with the higher mortality in patients who had a focus but no
procedure for source control, and with the survival benefit for
patients who underwent a procedure. The risk factors for death
identified in this study are comparable to those reported elsewhere.
An awareness of those patient groups at high risk for death can
Table 3. Association between clinical presentation and presence of Panton-Valentine Leukocidin (PVL) in the infecting isolate for
248 patients with S. aureus infection.
Clinical presentations Total no. of patients (n=248) PVL positive (n=122) PVL negative (n=126) p value*
1
Bacteraemia only, no identified site of infection 29 (12%) 3 (2%) 26 (21%) ,0.001
Superficial abscesses 80 (32%) 60 (49%) 20 (16%) ,0.001
Deep abscesses 43 (17%) 31 (25%) 12 (10%) 0.001
Other skin and soft tissue infections 28 (11%) 8 (7%) 20 (16%) 0.026
Bone and joint infections 25 (10%) 12 (10%) 13 (10%) .0.999
Prosthetic material infections 24 (10%) 2 (2%) 22 (17%) ,0.001
Respiratory infections 19 (8%) 8 (7%) 11 (9%) 0.635
- Pneumonia*
2 11 (4%) 5 (4%) 6 (5%) .0.999
Endocarditis 7 (3%) 2 (2%) 5 (4%) 0.447
Other infections 7 (3%) 5 (4%) 2 (2%) 0.275
Post-operative infections 4 (2%) 0 4 (3%) 0.122
Data are number (%). Denominator is the site of clinical presentation rather than patients.
*1p value for the comparison between PVL positive and PVL negative cases.
*2Subset of respiratory infections with pneumonia.
doi:10.1371/journal.pone.0006512.t003
Table 4. Significant risk factors for mortality from S. aureus
infection from multiple logistic regression analysis.
All-cause mortality Odds ratio (95% CI)*
1 p value*
2
Age 1.03 (1.01–1.05) ,0.001
Underlying cardiac disease 10.43 (2.96–36.70) ,0.001
Respiratory infection 6.46 (2.13–19.62) 0.001
Abscesses (superficial and deep
combined)
0.13 (0.04–0.40) ,0.001
Procedure for infectious source
control
0.22 (0.10–0.51) ,0.001
*195% confidence intervals.
*2p value from Likelihood ratio test.
doi:10.1371/journal.pone.0006512.t004
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facilities are available but limited and healthcare workers have a
large patient caseload.
Nosocomial infection and drug resistance are the focus of
enormous research efforts and expenditure in the developed world.
In developing countries worldwide, these are generally poorly
understood although there is wide variability. Nosocomial
infection is probably common, the reasons for which may include
lack of hand wash basins and/or hand washing, overcrowding in
hospital wards and clinics, lack of infection control training or
policies, an inability to isolate specific patients, and a lack of
awareness of the presence of nosocomial infection resulting from a
lack of diagnostic microbiology facilities. Drug resistance is also
likely to be underestimated in regions with little or no
microbiology capacity, and is probably driven in such settings by
the availability of a range of over-the-counter antibiotics. The
importance of both nosocomial infection and drug resistance were
highlighted by our study. Nearly one third of infections were
nosocomial or non-nosocomial healthcare-associated, and patients
in these groups had significantly higher mortality rates for both all-
cause and S. aureus-attributable deaths. Infection with MRSA was
either nosocomial or non-nosocomial healthcare-associated, and
was independently associated with all-cause and attributable
mortality. Those patients affected by healthcare-associated
infection often have other risk factors for death such as
prematurity, old age, underlying medical conditions or have
undergone recent surgery and the high mortality rate is not
surprising. However, these infections and infection-related deaths
are potentially preventable, and there is a clear need for studies in
such settings that evaluate low cost preventive interventions such
as a hand hygiene campaign associated with provision of improved
hand washing facilities or alcohol hand gel.
Nearly half of isolates causing S. aureus infection in patients
presenting to our hospital were PVL gene-positive, which is
significantly higher than that for previous reports for infecting
isolates amongst blood culture and skin infection samples from
Malaysia (5%) [28], skin infections in Bangladesh (14.3%) [29],
and blood culture (2.1%) and soft tissue infection samples (38.9%)
from the Netherlands [30]. This may imply that isolates that are
PVL gene-positive are more likely to cause infection than isolates
that are PVL gene-negative (that is, the rate of PVL gene-positivity
is lower in carriage than invasive strains). This could either be a
function of PVL per se, or could relate to one or more alternative
genes associated with disease acquisition that is in genetic linkage
with the PVL genes. Such questions will be addressed by us during
community carriage studies to determine rates of PVL gene
positivity, together with genotyping of carriage and invasive
isolates.
The role of PVL as a putative virulence determinant is a hotly
debated topic within the staphylococcal community, and this led
us to examine the association between this and both clinical
presentations and outcome. Our study design was robust in that
we recruited all patients with S. aureus infection who required
hospital treatment. Previous reports have been based on patient
subsets determined by clinical presentation [19], culture sample
type [17] or by being sent to a reference laboratory [18]. The
single most important finding was that PVL gene-positive isolates
were strongly associated with patient survival compared to PVL
gene-negative isolates. This may be explained in large part by the
fact that PVL gene-positive isolates were associated with skin and
soft tissue abscesses, an association reported previously [16,18,31]
and a clinical manifestation associated with low morbidity.
Community-acquired PVL-associated necrotising pneumonia
affecting previously fit people is often fatal and has gained
considerable notoriety. In our study we identified 3/270 patients
(1%) with PVL gene-positive, community-acquired pneumonia in
previously healthy individuals. None of these patients had
haemoptysis, which is deemed a major diagnostic criterion for
PVL-associated necrotising pneumonia [32], although none of the
prospective cases in the original paper by Gillet et al describing
PVL-associated necrotising pneumonia were described as having
had haemoptysis [19]. Two out of 3 of these patients died, but this
was in the context of a very high mortality of .80% for S. aureus
pneumonia overall. Although further cohort studies of unselected
patients are needed to determine the role of PVL as a virulence
factor in other geographic settings, the current study provides no
support for rapid PVL testing in this and other developing country
settings, where the focus should firmly rest with clinical
interventions that save lives.
In summary, this prospective cohort study has identified risk
factors for mortality in S. aureus disease and highlights clinical
strategies that reduce death. S. aureus is gaining increasing
recognition as an important pathogen in developing country
settings. Initiatives are required to optimise the use of available
resources and affordable interventions for patients with S. aureus
infection in the developing world.
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